Specialty Pharmacy

Top news of the day from across the health care landscape.

Patients with metastatic breast cancer who receive care aligned with National Comprehensive Cancer Network guidelines experienced less financial burden than patients who received guideline-discordant treatment.

Niraparib (Zejula) received approval for patients with advanced homologous recombination deficiency-positive status ovarian cancer who have received 3 or more prior chemotherapies.

Bemcentinib is being evaluated as a treatment for elderly patients with acute myeloid leukemia whose disease has relapsed.

Top news of the day from across the health care landscape.

The high cost of treating blood cancer may contribute to delayed initiation of active treatment in newly-diagnosed Medicare beneficiaries.

Researchers note that a metabolic imbalance in some patients with cancer following treatment with nivolumab is associated with shorter survival.

One in 8 pharmacies closed from 2009 to 2015, despite an overall increase in the number of pharmacies during this time.

Pegilodecakin in combination with pembrolizumab and nivolumab achieved measurable responses in patients with non-small cell lung cancer and kidney cancer.

Top news of the day from across the health care landscape.

At the ESMO Congress 2019, Sara Tolaney, MD, MPH, of Dana-Farber Cancer Institute, spoke about how a collaborative program between pharmacists and oncology providers at her institution helps prevent medication errors.

Elexacaftor/ivacaftor/tezacaftor (Trikafta, Vertex Pharmaceuticals) is indicated for patients aged 12 years and older with cystic fibrosis who have at least 1 F508del mutation.

Ustekinumab both induced and maintained clinical remission in a significantly greater proportion of adult patients with moderately to severely active ulcerative colitis compared with placebo.

Top news of the day from across the health care landscape.

Research explores why patients with mutated KRAS genes in tumor cells are sensitive to cetuximab.

Limited supply of chemotherapy agent that treats several pediatric cancers may lead to rationing of doses.

Ravulizumab-cwvz (Ultomiris, Alexion) is indicated to inhibit complement-mediated thrombotic microangiopathy in adult and pediatric patients with atypical hemolytic uremic syndrome.

The open-label Phase 2 trial looked to expand treatment for patients with newly diagnosed and persistent immune thrombocytopenia.

Top news of the day from across the health care landscape.

After participating in a sleep-education program, 41% of participants who survived cancer had their insomnia successfully treated.

Top news of the week from Specialty Pharmacy Times.

Pending results of the California Practice Standards and Jurisprudence Exam (CPJE) have been invalidated for 1400 applicants that recently took the test, due to a cheating issue.

Abrocitinib showed improvements in skin clearance and itch relief in patients aged 12 years and older with moderate-to-severe atopic dermatitis.

Glenmark Pharmaceuticals has received FDA approval for abiraterone acetate tablets USP, 250 mg, a generic of Janssen's Zytiga tablets, 250 mg.1

Study suggests that blocking a signaling pathway that includes the inflammatory factor CXCL10-CXCR3 may prevent brain metastasis.

Top news of the day from across the health care landscape.

Nine widely-used medications have experienced substantial price growth since 2016, adding $5.1 billion to overall drug spending.

The full-day meeting will feature recognized experts sharing the latest clinical data in oncology, while exploring best practices and management strategies.